The Role of Environmental Factors in the Development of Idiopathic Inflammatory Myopathies: a Narrative Review
- PMID: 37971581
- DOI: 10.1007/s11926-023-01120-x
The Role of Environmental Factors in the Development of Idiopathic Inflammatory Myopathies: a Narrative Review
Abstract
Purpose of review: This review aims to evaluate recent findings on the role of environmental factors in the development and clinical presentation of idiopathic inflammatory myopathies (IIMs).
Recent findings: A targeted literature review was conducted to identify reports relevant to the association between environmental factors and IIMs published over the past three years. There has been an increasing number of publications dealing with the association of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection or vaccination with the development of IIMs, highlighting the significant role of the antiviral immune response in the pathogenesis of the disease. Traditional environmental factors associated with the pathogenic process of IIM subclassifications included drugs such as statins and immune checkpoint inhibitors, ultraviolet radiation, smoking, air pollutants, and vitamin D deficiency. Correlations of seasonality and residence with the onset of certain IIM subtypes suggest a potential role of environmental triggers in the pathogenic process. An interplay between genetic predisposition and various environmental factors might contribute to the development of IIMs as well as the heterogeneous clinical and serological presentation of IIMs. The growing evidence on the role of environmental factors in the development of IIMs provides important clues to elucidate the pathophysiology of these disease entities. The mechanisms underlying the interactions between genetic predisposition and environmental factors should be investigated in the future.
Keywords: Environment; Idiopathic inflammatory myopathy; Immune-related adverse events; Myositis; SARS-CoV-2; Vaccination.
© 2023. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Similar articles
-
Environmental Risks for Inflammatory Myopathies.Rheum Dis Clin North Am. 2022 Nov;48(4):861-874. doi: 10.1016/j.rdc.2022.06.007. Rheum Dis Clin North Am. 2022. PMID: 36333000 Review.
-
Efficacy and safety of rituximab treatment in patients with idiopathic inflammatory myopathies: A systematic review and meta-analysis.Front Immunol. 2022 Dec 12;13:1051609. doi: 10.3389/fimmu.2022.1051609. eCollection 2022. Front Immunol. 2022. PMID: 36578492 Free PMC article.
-
Autophagy in myositis, a dysregulated pathway, and a target for therapy.Autoimmun Rev. 2025 Jun 24;24(7):103817. doi: 10.1016/j.autrev.2025.103817. Epub 2025 Apr 20. Autoimmun Rev. 2025. PMID: 40262692 Review.
-
Modern Therapies for Idiopathic Inflammatory Myopathies (IIMs): Role of Biologics.Clin Rev Allergy Immunol. 2017 Feb;52(1):81-87. doi: 10.1007/s12016-016-8530-2. Clin Rev Allergy Immunol. 2017. PMID: 26767526 Free PMC article. Review.
-
Idiopathic Inflammatory Myopathies: A Review of the Classification and Impact of Pathogenesis.Int J Mol Sci. 2017 May 18;18(5):1084. doi: 10.3390/ijms18051084. Int J Mol Sci. 2017. PMID: 28524083 Free PMC article. Review.
References
-
- Dalakas MC. Inflammatory muscle diseases. N Engl J Med. 2015;372:1734–47. https://doi.org/10.1056/NEJMra1402225 . - DOI - PubMed
-
- Lundberg IE, Tjärnlund A, Bottai M, Werth VP, Pilkington C, de Visser M, et al. 2017 European League Against Rheumatism/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups. Ann Rheum Dis. 2017;76:1955–64. https://doi.org/10.1136/annrheumdis-2017-211468 . - DOI - PubMed
-
- Lundberg IE, Fujimoto M, Vencovsky J, Aggarwal R, Holmqvist M, Christopher-Stine L, et al. Idiopathic inflammatory myopathies. Nat Rev Dis Primers. 2021;7:86. https://doi.org/10.1038/s41572-021-00321-x . - DOI - PubMed
-
- Miller FW, Lamb JA, Schmidt J, Nagaraju K. Risk factors and disease mechanisms in myositis. Nat Rev Rheumatol. 2018;14:255–68. https://doi.org/10.1038/nrrheum.2018.48.5 . - DOI - PubMed - PMC
-
- Gono T, Kawaguchi Y, Kuwana M, Sugiura T, Furuya T, Takagi K, et al. Brief report: Association of HLA-DRB1*0101/*0405 with susceptibility to anti-melanoma differentiation-associated gene 5 antibody-positive dermatomyositis in the Japanese population. Arthritis Rheum. 2012;64:3736–40. https://doi.org/10.1002/art.34657 . - DOI - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous